Bio-K Plus International Inc., Opens A Research Laboratory At INRS-Centre Armand-Frappier Santé Biotechnologie

During the Antibiotic Awareness Week, Bio-K Plus International Inc. announces the inauguration of its new basic and preclinical research laboratory at the INRS Center ArmandFrappier Health Biotechnology in Laval, Quebec.

As stated by the company's chief innovation officer, Pierre Falardeau, PhD: "This major laboratory expansion will allow the addition of state-of-the-art equipment to support our many research projects. and develop new products to meet customer needs. We want to stay ahead of the game in innovation and quality control that has been part of the company's DNA since it was founded. This is why we are delighted with the realization of this project, which is a continuation of our historic partnership with the INRS ".

Stéphane Roche, Director of Research and Academic Affairs at INRS adds: "We are pleased to welcome the BioK Plus research laboratories to the Armand-Frappier Health Biotechnology Center. Recent studies show how increasing research partnerships contributes not only to intensify the capacity for the valorisation and transfer of knowledge to the environment, but also to significantly increasing the impact of the scientific dissemination of the results in the scientific community. INRS has become a staple in the development of trusted partnerships. Our strength in fundamental and applied interdisciplinary research will allow us to innovate alongside Bio-K Plus."

For the past 10 years, the laboratory led by Mathieu Millette PhD, has been working to highlight the mechanisms of actions supporting the effectiveness of Bio-K Plus products in the fight against Clostridioides (Clostridium) difficile and against diarrhea associated with taking antibiotics. In fact, Bio-K Plus is used in more than 100 hospitals in Canada and the USA for the prevention of primary C. difficile. In addition to developing new methods to characterize the 3 probiotic strains that have made the company successful, the laboratory is essential to support the company's quality assurance program, which remains one of the few companies in the world of probiotics to be vertically integrated, from discovery to development, to production, to distribution.

Current research projects include Irritable Bowel Syndrome for which Bio-K Plus has recently received an allegation from Health Canada.

With this new investment, Bio-K Plus is once again demonstrating its interest to remain a major player in probiotic research and their multiple therapeutic interactions with their host.